Select Bibliography

Filter by any of these (after searching):

There are 21 items

Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS) CALGB 100104 (Alliance)

Attal, Michel , Palumbo, Antonio , Holstein, Sarah ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma

Holstein, Sarah A. , Jung, Sin-Ho , Richardson, Paul G. ... - - Lancet Haematol - 2017

Manuscript - Primary - Long-Term-Followup - Myeloma - CALGB-100104

Updated analysis of CALGB 100104: lenalidomide (Len) vs. placebo maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).

Holstein, Sarah A. , Owzar, Kouros , Richardson, Paul G. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary - Long-Term-Followup - Myeloma - CALGB-100104

Long-term follow-up of CALGB (Alliance) 100001: Autologous followed by non-myeloablative allogeneic transplant for multiple myeloma

Holstein, Sarah A. , Suman, Vera J. , Owzar, Kouros , Santo, Katelyn ... - - Biol. Blood Marrow Transplant. - 2020

Manuscript - Primary - Long-Term-Followup - Myeloma - CALGB-100001

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of GRIFFIN After 12-months of Maintenance Therapy (AFT-29)

Kaufman, Jonathan L. , Laubach, Jacob , Sborov, Douglas W. ... - ASH - Blood - 2020

Abstract - Primary - Long-Term-Followup - Myeloma - AFT-29

Overall and Progression-Free Survival Adjusted for Treatment Crossover in the CALGB 100104 Study of Lenalidomide Versus Placebo Maintenance After Stem Cell Transplant for Patients With Newly Diagnosed Multiple Myeloma (Alliance)

McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - IMW - - 2017

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

CALGB/ECOG 100104 (Alliance) Study: Lenalidomide (LEN) vs Placebo (PBO) Maintenance (Maint) After Stem Cell Transplant (SCT) for Patients (Pts) With Multiple Myeloma: Overall Survival (OS) and Progression-Free Survival (PFS) Adjusted for Treatment (Tx) Crossover (XO)

McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Lenalidomide vs Placebo Maintenance After Stem Cell Transplant for Patients With Multiple Myeloma: Overall Survival and Progression-Free Survival After Adjusting for Treatment Crossover in CALGB

McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - EHA - Haematologica - 2017

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

McCarthy, Philip L. , Holstein, Sarah A. , Petrucci, Maria Teresa ... - - J. Clin. Oncol - 2017

Manuscript - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

McCarthy, Philip L. , Owzar, Kouros , Hofmeister, Craig C. ... - - N. Engl. J. Med. - 2012

Manuscript - Primary - Primary - Myeloma - CALGB-100104

Survival analysis from the CALGB trial of lenalidomide (LEN) maintenance therapy in newly diagnosed multiple myeloma (NDMM) post-autologous stem cell transplant (ASCT), adjusting for crossover (Alliance)

McCarthy, Philip L. , Suman, Vera , Cooper, Miranda , Saunders, Owain ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Analysis Of Overall Survival (OS) In The Context Of Cross-Over From Placebo To Lenalidomide And The Incidence Of Second Primary Malignancies (SPM) In The Phase III Study Of Lenalidomide Versus Placebo Maintenance Therapy Following Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) CALGB (Alliance) ECOG BMT-CTN 100104

Mccarthy, P. , Owzar, K. , Hofmeister, C. , Richardson, P. ... - IMW - Clin Lymphoma Myeloma Leuk - 2013

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Daratumumab (DARA) + Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) With Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN

Nooka, Ajay K. , Kaufman, Jonathan L. , Rodriguez, Cesar ... - SOHO - - 2020

Abstract - Secondary-not-in-original - Primary - Myeloma - AFT-05

Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN AFT-29

Voorhees, Peter M. , Kaufman, Jonathan L. , Laubach, Jacob ... - IMW - - 2019

Abstract - Primary - Primary - Myeloma - AFT-29

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Voorhees, Peter M. , Kaufman, Jonathan L. , Laubach, Jacob ... - - Blood - 2020

Manuscript - Primary - Primary - Myeloma - AFT-29

Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVD) improves over time in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): GRIFFEN study update (AFT-29)

Voorhees, Peter M. , Kaufman, Jonathan L. , Laubach, Jacob ... - ASH - Blood - 2019

Abstract - Secondary - Primary - Myeloma - AFT-29

Interim safety analysis of a phase 2 randomized study of daratumumab (dara), lenalidomide (r), bortezomib (v), and dexamethasone (d; dara‐rvd) vs. rvd in patients (pts) with newly diagnosed multiple myeloma (mm) eligible for high‐dose therapy (hdt) and autologous stem cell transplantation (asct)

Voorhees, Peter M. , Morris, Michael , Costa, Luciano J. ... - ASH - Blood - 2017

Abstract - Secondary - Preliminary - Myeloma - AFT-29

Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor based therapy: Phase I results.

Voorhees, Peter M. , Mulkey, Flora , Hassoun, Hani ... - ASH - Blood - 2015

Abstract - Primary - Primary - Myeloma - A061202

Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN

Voorhees, Peter M. , Rodriguez, Cesar , Reeves, Brandi ... - - Blood Adv - 2021

Manuscript - Secondary - Long-Term-Followup - Myeloma - AFT-29

Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Voorhees, Peter M. , Rodriguez, Cesar , Reeves, Brandi ... - ASH - Blood - 2018

Abstract - Primary - Primary - Myeloma - AFT-29

Depth of Response to Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone Improves Over Time in Patients With Transplant-Eligible Newly Diagnosed Multiple Myeloma: GRIFFIN Study Update

Voorhees, Peter M , Kaufman, Jonathan L , Laubach, Jacob ... - EBMT - Bone Marrow Transplantation - 2020

Abstract - Secondary - Primary - Myeloma - AFT-29